Oncology

Ripretinib is a kinase inhibitor indicated for adults with advanced GIST, approved by the FDA in May 2020.

Apalutamide in combination with ADT prolonged median OS by 14 months and decreased the risk of death by 22%. Further, median OS was significantly longer, with 73.9 months for patients receiving treatment with apalutamide in combination with ADT compared with 59.9 months for patients receiving placebo in combination with ADT.

Interventions such as exercise programs and discharge planning efforts have been promising in addressing functional impairment and improving post-discharge outcomes.

According to a recent study, diet can affect the outcome of chemotherapy due to microbes in the gut that can trigger changes in a patient’s response to drugs.

The investigational, marine-derived small-molecule binds to and affects the function of the protein tubulin within cells of the body.

In the new data cut-offs from both studies, the survival advantages for the combination with fulvestrant and combination with an aromatase inhibitor were shown, but major disadvantages were also evident, according to the IQWiG.

This Peer Exchange Webinar will provide insights into use of PARP inhibitors in the treatment of ovarian cancer.

The recent analysis of VB-111 was a phase 3 potential registration study conducted with 400 patients and 95 sites around the world.

According to a recent study, olanzapine may help patients with advanced cancer manage symptoms unrelated to chemotherapy, such as nausea and vomiting.

“Providing quality of care in a field of cancer risk, genetics, and prevention revolves around 3 essential interdependent components,” said presenter Erin Wysong Hofstatter, MD.

At the 2020 ASCO Annual Meeting, speaker Leslie R. Ellis, MD, MSHPEd, FACP, discussed the results of studies in a session looking into current research on leukemia, MDS, and allotransplant.

Results of the COVID-19 and Cancer Consortium cohort study were presented during the virtual science program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

A study found that nurse-led follow-up and mobile health app leads to improved relative dose intensity, patient experiences, hospitalizations and their duration, and the rate of treatment-related grade 3 or higher toxicities.

The presence of ongoing SHM or CSR in the context of CLL may support the functionality of DNA damage repair pathways, with potential relevance to therapeutic strategies.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor and is approved in the United States for first-line treatment of patients with metastatic NSCLC with tumors that have EGFR mutations (exon 19 deletions or exon 21 L858R mutations).

This study was the first to demonstrate efficacy of front-line treatment in the period after initial chemotherapy.

The results of the new study were presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

Daunorubicin and cytarabine liposome for injection is a dual-drug liposomal encapsulation of cytarabine and daunorubicin approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.

The recent analysis studied 400 patients with thoracic cancers who received chemotherapy within 3 months of being diagnosed with COVID-19.

Trastuzumab deruxtecan (T-DXd) (Enhertu) demonstrated strong efficacy in a phase 2 trial for treatment of HER2-positive metastatic breast cancer.

Treatment with avelumab (Bavencio) potentially cured 8 of 15 women in a trial with gestational trophoblastic tumors resistant to single-agent chemotherapy.

Atezolizumab (Tecentriq) approved in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

In 2017 alone, there was an estimated 785 fewer cancer deaths in states that adopted Medicaid expansion.

At 5 years follow up, the data showed that the OS for women on olaparib was 42.1%, while the placebo OS was 33.2%.

Pharmacy Times® spoke with Jennifer Craig, PharmD, CSP, about Skin Cancer Awareness Month and the importance of skin care.

Lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck) showed significant response rates in unresectable hepatocellular carcinoma and in patients with metastatic clear cell renal cell carcinoma who progressed following immune checkpoint inhibitor therapy.

Treatment of COVID-19 with both hydroxychloroquine and azithromycin also was strongly associated with increased risk of death.

FDA has granted Fast Track designation to Cardiff Oncology’s onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

ASCO’s special report summarizes a wide range of policies and practices developed by cancer facilities, as well as guidance provided by government agencies and other medical societies.

The therapy is approved for patients with squamous or non-squamous disease and regardless of programmed death-ligand 1 (PD-L1) expression.